Fenwick & West represented Neoleukin Therapeutics, Inc in the transaction. Neoleukin Therapeutics closed its public offering of 10,263,750 shares of its common stock at a public…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
